ArticleMedicine2026
Predictive role of blood urea nitrogen to serum albumin ratio (BAR) in all-cause mortality in patients with cirrhosis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to assess the potential association between the blood urea nitrogen to serum albumin ratio (BAR) and all-cause mortality (ACM) in cirrhosis patients. We used X-tile software (V 3.6.1; Yale University, New Haven) to obtain the cutoff value and group the subjects. We applied 1:1 propensity score matching to reduce confounders. The primary endpoint events included ACM at 30, 90, and 365 days. The association between BAR and ACM was investigated using multivariable Cox regression analyses and Kaplan-Meier survival curves. After propensity score matching, we included 746 matched patient pairs based on a cutoff of 9.3. There were no significant differences in 30- and 90-day ACM rates between the 2 groups, while the 365-day ACM rates were 361 (48.4%) and 409 (54.8%; P = .013), respectively. Additionally, the multivariable Cox regression analysis showed that BAR was significantly associated with an increased risk of 365-day ACM, with a hazard ratio of 1.18 and a 95% confidence interval of 1.03 to 1.36; P = .022. The survival analysis showed that the low BAR group had a higher survival probability within 365 days (log-rank P = .046). BAR may be associated with 365-day mortality in hepatic cirrhosis patients in intensive care units.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.